Filsuvez® gel helps EB wounds to heal.

Over 200 adults and children with Dystrophic, Junctional and Kindler EB were involved in a phase 3 clinical trial that produced the evidence that Filsuvez® gel helped wounds to close more quickly.

41% showed complete wound closure within 45 days compared to 29% using a placebo gel that did not contain the active ingredient. During the initial 90-day treatment period, 32% of participants given Filsuvez® required daily wound dressing changes compared to 50% of those using the placebo, and those treated with Filsuvez® reported reduced pain when dressings were changed. More recent trial data showed that the percentage of the body surface area that was wounded decreased on average by more than half for DEB patients after 15 months using Filsuvez®.